| 1 |
Graded, multidimensional intra- and intergroup variations in primary progressive aphasia and post-stroke aphasia.
|
|
|
|
In: Brain : a journal of neurology, vol 143, iss 10 (2020)
|
|
BASE
|
|
Show details
|
|
|
| 2 |
More Than Smell-COVID-19 Is Associated With Severe Impairment of Smell, Taste, and Chemesthesis.
|
|
|
|
In: Chemical senses, vol 45, iss 7 (2020)
|
|
BASE
|
|
Show details
|
|
|
| 3 |
Quantal biomechanical effects in speech postures of the lips.
|
|
|
|
In: Journal of neurophysiology, vol 124, iss 3 (2020)
|
|
BASE
|
|
Show details
|
|
|
| 4 |
C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTLD cohorts.
|
|
|
|
In: Neurology, vol 95, iss 24 (2020)
|
|
BASE
|
|
Show details
|
|
|
| 5 |
Language disparity is not a significant barrier for time-sensitive care of acute ischemic stroke.
|
|
|
|
In: BMC neurology, vol 20, iss 1 (2020)
|
|
BASE
|
|
Show details
|
|
|
| 6 |
Factors that predict diagnostic stability in neurodegenerative dementia.
|
|
|
|
In: Journal of neurology, vol 266, iss 8 (2019)
|
|
BASE
|
|
Show details
|
|
|
| 7 |
Factors that predict diagnostic stability in neurodegenerative dementia.
|
|
|
|
In: Journal of neurology, vol 266, iss 8 (2019)
|
|
BASE
|
|
Show details
|
|
|
| 8 |
Anomalous morphology in left hemisphere motor and premotor cortex of children who stutter
|
|
|
|
BASE
|
|
Show details
|
|
|
| 9 |
Anterior insular thickness predicts speech sound learning ability in bilinguals.
|
|
|
|
In: NeuroImage, vol 165 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 10 |
New Directions in Treatments Targeting Stroke Recovery.
|
|
|
|
In: Stroke, vol 49, iss 12 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 11 |
Human Sensorimotor Cortex Control of Directly Measured Vocal Tract Movements during Vowel Production.
|
|
|
|
In: The Journal of neuroscience : the official journal of the Society for Neuroscience, vol 38, iss 12 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 12 |
Large-scale associations between the leukocyte transcriptome and BOLD responses to speech differ in autism early language outcome subtypes.
|
|
|
|
In: Nature neuroscience, vol 21, iss 12 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 13 |
Large-scale associations between the leukocyte transcriptome and BOLD responses to speech differ in autism early language outcome subtypes.
|
|
|
|
In: Nature neuroscience, vol 21, iss 12 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 14 |
Peak alpha frequency is a neural marker of cognitive function across the autism spectrum.
|
|
|
|
In: The European journal of neuroscience, vol 47, iss 6 (2018)
|
|
BASE
|
|
Show details
|
|
|
| 15 |
Observing conversational laughter in frontotemporal dementia.
|
|
|
|
In: Journal of neurology, neurosurgery, and psychiatry, vol 88, iss 5 (2017)
|
|
BASE
|
|
Show details
|
|
|
| 16 |
Observing conversational laughter in frontotemporal dementia.
|
|
|
|
In: Journal of neurology, neurosurgery, and psychiatry, vol 88, iss 5 (2017)
|
|
BASE
|
|
Show details
|
|
|
| 17 |
Language structure in the brain: A fixation-related fMRI study of syntactic surprisal in reading.
|
|
|
|
BASE
|
|
Show details
|
|
|
| 18 |
Dynamic Structure of Neural Variability in the Cortical Representation of Speech Sounds.
|
|
|
|
In: The Journal of neuroscience : the official journal of the Society for Neuroscience, vol 36, iss 28 (2016)
|
|
BASE
|
|
Show details
|
|
|
| 19 |
Therapy and clinical trials in frontotemporal dementia: past, present, and future.
|
|
|
|
In: Journal of neurochemistry, vol 138 Suppl 1, iss S1 (2016)
|
|
Abstract:
Frontotemporal dementia (FTD) is a common form of dementia with heterogeneous clinical presentations and distinct clinical syndromes. This article will review currently available therapies for FTD, its related disorders and their clinical evidence. It will also discuss recent advancements in FTD pathophysiology, treatment development, biomarker advancement and their relation to recently completed or currently ongoing clinical trials as well as future implications. Frontotemporal dementia (FTD) is a type of dementia with distinct clinical syndromes. Current treatments involve off-label use of medications for symptomatic management and cannot modify disease course. Advancements in FTD pathophysiology, genetics, and biomarkers have led to development of small molecules targeting the underlying pathology in hopes of achieving a disease-modifying effect. This article will review current therapies for FTD, discuss advancements in FTD pathophysiology, therapy development, biomarker advancement, their relation to recent clinical trials and future implications. This article is part of the Frontotemporal Dementia special issue.
|
|
Keyword:
10th International Conference on Frontotemporal Dementia; Acquired Cognitive Impairment; Aging; Alzheimer's Disease including Alzheimer's Disease Related Dementias; Alzheimer's Disease Related Dementias; behavioral variant frontotemporal dementia; Biochemistry and Cell Biology; Biomarkers; Brain Disorders; C9ORF72; clinical trials; Clinical Trials as Topic; Dementia; Frontotemporal Dementia; Humans; Neurodegenerative; Neurological; Neurology & Neurosurgery; Neurosciences; Prevention; primary progressive aphasia; progressive supranuclear palsy; Rare Diseases; tau; TDP-43; treatment
|
|
URL: https://escholarship.org/uc/item/45c2w73b
|
|
BASE
|
|
Hide details
|
|
|
|
|
